140 related articles for article (PubMed ID: 29340049)
1. Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancer.
Gravina GL; Mancini A; Colapietro A; Marampon F; Sferra R; Pompili S; Biordi LA; Iorio R; Flati V; Argueta C; Landesman Y; Kauffman M; Shacham S; Festuccia C
Oncotarget; 2017 Dec; 8(67):111225-111245. PubMed ID: 29340049
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of Docetaxel-Induced Cytotoxicity in Human PC-3 Androgen-Independent Prostate Cancer Cells by Combination With Four Natural Apoptosis-Inducing Anticancer Compounds.
Ahmed IA; Hafiz S; van Ginkel S; Pondugula SR; Abdelhaffez AS; Sayyed HG; El-Aziz EAA; Mansour MM
Nat Prod Commun; 2023 May; 18(5):. PubMed ID: 37292146
[TBL] [Abstract][Full Text] [Related]
3. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.
Ishov A; Sarwar S; Morozov V; Newcomb M; Guryanova O
Res Sq; 2024 Apr; ():. PubMed ID: 38746435
[TBL] [Abstract][Full Text] [Related]
4. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives.
Talati C; Sweet KL
Int J Hematol Oncol; 2018 Oct; 7(3):IJH04. PubMed ID: 30405902
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Effect by Combined Treatment of
Jung EJ; Kim HJ; Shin SC; Kim GS; Jung JM; Hong SC; Chung KH; Kim CW; Lee WS
Curr Issues Mol Biol; 2024 Feb; 46(2):1621-1634. PubMed ID: 38392223
[TBL] [Abstract][Full Text] [Related]
6. First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.
Tomasello G; Valeri N; Ghidini M; Smyth EC; Liguigli W; Toppo L; Mattioli R; Curti A; Hahne JC; Negri FM; Panni S; Ratti M; Lazzarelli S; Gerevini F; Colombi C; Panni A; Rovatti M; Treccani L; Martinotti M; Passalacqua R
Oncotarget; 2017 Dec; 8(67):111795-111806. PubMed ID: 29340092
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of PTEN loss in prostate cancer.
Jamaspishvili T; Berman DM; Ross AE; Scher HI; De Marzo AM; Squire JA; Lotan TL
Nat Rev Urol; 2018 Apr; 15(4):222-234. PubMed ID: 29460925
[TBL] [Abstract][Full Text] [Related]
9. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Huang A; Wang L; Baser O; Miao R
BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.
Fang M; Nakazawa M; Antonarakis ES; Li C
Prostate Cancer; 2017; 2017():8560827. PubMed ID: 29359049
[TBL] [Abstract][Full Text] [Related]
11. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer.
Dell'Oglio P; Bandini M; Leyh-Bannurah SR; Tian Z; Trudeau V; Larcher A; Fossati N; Moschini M; Gandaglia G; Capitanio U; Briganti A; Graefen M; Montorsi F; Saad F; Karakiewicz PI
Urol Oncol; 2018 May; 36(5):239.e9-239.e15. PubMed ID: 29426698
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Yamamoto A; Kato M; Matsui H; Ishida R; Kimura T; Funahashi Y; Sassa N; Matsukawa Y; Kamihira O; Hattori R; Gotoh M; Tsuzuki T
Int J Clin Oncol; 2018 Jun; 23(3):584-590. PubMed ID: 29397469
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Ahlgren GM; Flodgren P; Tammela TLJ; Kellokumpu-Lehtinen P; Borre M; Angelsen A; Iversen JR; Sverrisdottir A; Jonsson E; Sengelov L;
Eur Urol; 2018 Jun; 73(6):870-876. PubMed ID: 29395502
[TBL] [Abstract][Full Text] [Related]
15. Effect of dutasteride on castration-resistant prostate cancer.
Azuma T; Matayoshi Y; Sato Y; Nagase Y
Mol Clin Oncol; 2018 Jan; 8(1):133-136. PubMed ID: 29387405
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.
Cavo A; Rubagotti A; Zanardi E; Fabbroni C; Zinoli L; Di Meglio A; Arboscello E; Bellodi A; Spallarossa P; Cattrini C; Messina C; Boccardo F
Ther Adv Med Oncol; 2018; 10():1758834017745819. PubMed ID: 29383035
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
18. Differential role of PTEN in transforming growth factor β (TGF-β) effects on proliferation and migration in prostate cancer cells.
Kimbrough-Allah MN; Millena AC; Khan SA
Prostate; 2018 Apr; 78(5):377-389. PubMed ID: 29341212
[TBL] [Abstract][Full Text] [Related]
19. Older Age, Early Symptoms and Physical Function are Associated with the Severity of Late Symptom Clusters for Men Undergoing Radiotherapy for Prostate Cancer.
Lemanska A; Dearnaley DP; Jena R; Sydes MR; Faithfull S
Clin Oncol (R Coll Radiol); 2018 Jun; 30(6):334-345. PubMed ID: 29459102
[TBL] [Abstract][Full Text] [Related]
20. Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Beauval JB; Loriot Y; Hennequin C; Rozet F; Barthelemy P; Borchiellini D; Schlürmann Constans F; Gross E; Maillet D; Pasticier G; Pignot G; Timsit MO; Vincendeau S; Ploussard G; Sargos P
Crit Rev Oncol Hematol; 2018 Feb; 122():144-149. PubMed ID: 29458782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
